<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01000844</url>
  </required_header>
  <id_info>
    <org_study_id>01-436</org_study_id>
    <nct_id>NCT01000844</nct_id>
  </id_info>
  <brief_title>Joint Outcome Study Continuation for Children With Severe Factor VIII Deficiency</brief_title>
  <acronym>JOSC</acronym>
  <official_title>Continuation of Children Enrolled in Protocol #95-011, 'A Randomized Prospective Study for the Prevention of Joint Disease in Children With Severe Factor VIII Deficiency'</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Phoenix Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Prisma Health-Midlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Intermountain Health Care, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ann &amp; Robert H Lurie Children's Hospital of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The original Joint Outcome Study (JOS) enrolled 65 boys with hemophilia from 16 sites
      nationally. The subjects were randomized to one of two arms (prophylaxis or an enhanced
      episode-based treatment)and were followed prospectively until the age of six. At the age of
      six, the proportion of children on each treatment arm who developed bone or cartilage damage
      as determined by X-Ray or MRI was assessed. In addition, the function and structure of the
      index joints (defined as knees, ankles, and elbows)were evaluated using a physical assessment
      scale specially designed for preschool children.

      The specific aim of the Joint Outcome Study Continuation (JOSC) is to extend observations of
      the children participating in the original JOS until the subjects reach the age of 18 years
      in order to determine the natural history of joint development in hemophilia and the impact
      of primary or secondary prophylaxis on the prevention, limitation, or reversal of hemophilic
      arthropathy. In addition, plasma and DNA will be collected and banked yearly for current and
      future studies of biomarkers and predictors of hemophilia outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the natuaral history of joint development in hemophilia and the impact of primary or secondary prophylaxis on the prevention, limitation, or reversal of hemophilic arthropathy.</measure>
    <time_frame>Enrollment, age 14, and study exit at age 18</time_frame>
  </primary_outcome>
  <enrollment type="Actual">11</enrollment>
  <condition>Hemophilia</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole Blood - EDTA, Citrate Plasma, and DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Study population will be invited based on their enrollment in the original Joint Outcome
        Study (JOS). This population
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Enrolled in the original JOS study, &quot;A Randomized Prospective Study for the Prevention
             of Joint Disease in Children with Factor VIII Deficiency&quot;

          -  Written, informed consent of parent or guardian for the proposed study

          -  The local hemophilia treatment center staff must evaluate the family's participation
             in the original treatment protocol and determine that the family is capable of
             complying with the continuation protocol

        Exclusion Criteria:

          -  Unable or unwilling to record the study information
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marilyn Manco-Johnson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado at Denver Health and Sciences Center</affiliation>
  </overall_official>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 22, 2009</study_first_submitted>
  <study_first_submitted_qc>October 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2009</study_first_posted>
  <last_update_submitted>October 29, 2019</last_update_submitted>
  <last_update_submitted_qc>October 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemophilia</keyword>
  <keyword>Joint</keyword>
  <keyword>Cartilage</keyword>
  <keyword>Damage</keyword>
  <keyword>Prophylaxis</keyword>
  <keyword>Factor VIII</keyword>
  <keyword>FVIII</keyword>
  <keyword>Disease</keyword>
  <keyword>Arthropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

